Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs

Molecular Pharmacology

Volumn 77, Issue 6, 2010, Pages 887-894

  Howell, Stephen B ^a   Safaei, Roohangiz ^a   Larson, Christopher A ^a   Sailor, Michael J ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; COPPER; COPPER TRANSPORTER 1; CYSTEINE; METHIONINE; OXALIPLATIN; PEROXIREDOXIN 3; PLATINUM DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

CHELATION; COPPER HOMEOSTASIS; CYTOTOXICITY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; HOMEOSTASIS; HUMAN; IN VIVO CULTURE; NONHUMAN; OVARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CATION TRANSPORT PROTEINS; CISPLATIN; COPPER; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROTEIN CONFORMATION;

EID: 77952341427     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.063172     Document Type: Short Survey

References (79)

1. Aller SG, Eng ET, De Feo CJ, and Unger VM (2004) Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. J Biol Chem 279:53435-53441.
2. 1+ transporter of intestinal cells. Am J Physiol Cell Physiol 284:C1525-C1530.
3. Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, and Perego P (2004) Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 68:283-291. (Pubitemid 38757697)
4. Boal AK and Rosenzweig AC (2009) Crystal structures of cisplatin bound to a human copper chaperone. J Am Chem Soc 131:14196-14197.
5. Dancis A, Haile D, Yuan DS, and Klausner RD (1994) The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem 269:25660-25667.
6. De Feo CJ, Aller SG, Siluvai GS, Blackburn NJ, and Unger VM (2009) Three-dimensional structure of the human copper transporter hCTR1. Proc Natl Acad Sci USA 106:4237-4242.
7. De Feo CJ, Aller SG, and Unger VM (2007) A structural perspective on copper uptake in eukaryotes. Biometals 20:705-716.
8. Eisses JF, Chi Y, and Kaplan JH (2005) Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. J Biol Chem 280:9635-9639. (Pubitemid 40409660)
9. Eisses JF and Kaplan JH (2002) Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem 277:29162-29171.
10. Eisses JF and Kaplan JH (2005) The mechanism of copper uptake mediated by human CTR1: a mutational analysis. J Biol Chem 280:37159-37168.
11. Guo Y, Smith K, Lee J, Thiele DJ, and Petris MJ (2004) Identification of methioninerich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J Biol Chem 279:17428-17433.
12. Hall MD, Okabe M, Shen DW, Liang XJ, and Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495-535. (Pubitemid 351738162)
13. Haremaki T, Fraser ST, Kuo YM, Baron MH, and Weinstein DC (2007) Vertebrate Ctr1 coordinates morphogenesis and progenitor cell fate and regulates embryonic stem cell differentiation. Proc Natl Acad Sci USA 104:12029-12034. (Pubitemid 47185624)
14. Holzer AK and Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952.
15. Holzer AK, Katano K, Klomp LW, and Howell SB (2004a) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744-6749. (Pubitemid 39346572)
16. Holzer AK, Manorek GH, and Howell SB (2006a) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390-1394.
17. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, and Howell SB (2004b) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817-823. (Pubitemid 39319453)
18. Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P, and Howell SB (2006b) Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 54:1041-1049. (Pubitemid 44298591)
19. Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302.
20. Itoh S, Kim HW, Nakagawa O, Ozumi K, Lessner SM, Aoki H, Akram K, McKinney RD, Ushio-Fukai M, and Fukai T (2008) Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem 283:9157-9167.
21. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, and Howell SB (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553-560.
22. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, and Howell SB (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559-6565. (Pubitemid 35364122)
23. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, and Howell SB (2003) The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:466-473. (Pubitemid 36910011)
24. Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, and Howell SB (2004) Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 10:4578-4588. (Pubitemid 38878902)
25. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
26. Klomp AE, Juijn JA, van der Gun LT, van den Berg IE, Berger R, and Klomp LW (2003) The N-terminus of the human copper transporter 1 (hCTR1) is localized extracellularly, and interacts with itself. Biochem J 370:881-889. (Pubitemid 36399080)
27. Klomp AE, Tops BB, Van Denberg IE, Berger R, and Klomp LW (2002) Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). Biochem J 364:497-505. (Pubitemid 34620810)
28. Kuo YM, Zhou B, Cosco D, and Gitschier J (2001) The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA 98:6836-6841.
29. Larson CA, Blair BG, Safaei R, and Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330.
30. Lee J, Peñ a MM, Nose Y, and Thiele DJ (2002a) Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 277:4380-4387.
31. Lee J, Petris MJ, and Thiele DJ (2002b) Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem 277:40253-40259.
32. Lee J, Prohaska JR, Dagenais SL, Glover TW, and Thiele DJ (2000) Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 254:87-96.
33. Lee J, Prohaska JR, and Thiele DJ (2001) Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci USA 98:6842-6847. (Pubitemid 32538304)
34. Lee S, Howell SB, and Opella SJ (2007) NMR and mutagenesis of human copper transporter 1 (hCtr1) show that Cys-189 is required for correct folding and dimerization. Biochim Biophys Acta 1768:3127-3134.
35. Liang XJ, Shen DW, Garfield S, and Gottesman MM (2003) Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 63:5909-5916.
36. Liang ZD, Stockton D, Savaraj N, and Tien Kuo M (2009) Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol 76:843-853.
37. Lin X, Okuda T, Holzer A, and Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154-1159.
38. Liu J, Sitaram A, and Burd CG (2007) Regulation of copper-dependent endocytosis and vacuolar degradation of the yeast copper transporter, Ctr1p, by the Rsp5 ubiquitin ligase. Traffic 8:1375-1384.
39. Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, and McKeage MJ (2009) Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 64:847-856.
40. Martell A and Hancock R (1996) Metal Complexes in Aqueous Solutions, Plenum Press, New York.
41. Maryon EB, Zhang J, Jellison JW, and Kaplan JH (2009) Human copper transporter 1 lacking O-linked glycosylation is proteolytically cleaved in a Rab9-positive endosomal compartment. J Biol Chem 284:28104-28114.
42. Matsumoto S, Tanaka T, Kurokawa H, Matsuno K, Hayashida Y, and Takahashi T (2007) Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 27:2209-2216.
43. Molloy SA and Kaplan JH (2009) Copper-dependent recycling of hCTR1, the human high affinity copper transporter. J Biol Chem 284:29704-29713.
44. Nakagawa H, Ohira M, Hayashi S, Abe S, Saito S, Nagahori N, Monde K, Shinohara Y, Fujitani N, Kondo H, et al. (2008) Alterations in the glycoform of cisplatinresistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system. Cancer Lett 270:295-301.
45. Nicol BM and Prasad SB (2002) Sialic acid changes in Dalton's lymphoma-bearing mice after cyclophosphamide and cisplatin treatment. Braz J Med Biol Res 35: 549-553.
46. Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, and Peters GJ (2008) Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem Pharmacol 76:53-61.
47. Ooi CE, Rabinovich E, Dancis A, Bonifacino JS, and Klausner RD (1996) Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO J 15:3515-3523.
48. Pabla N, Murphy RF, Liu K, and Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505-F511.
49. Petris MJ (2004) The SLC31 (Ctr) copper transporter family. Pflugers Arch 447:752-755.
50. Petris MJ, Smith K, Lee J, and Thiele DJ (2003) Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 278:9639-9646. (Pubitemid 36800460)
51. Puig S, Lee J, Lau M, and Thiele DJ (2002) Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem 277:26021-26030.
52. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, and O'Halloran TV (1999) Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284:805-808.
53. Reedijk J (1999) Why does cisplatin reach guanine-n7 with competing s-donor ligands available in the cell? Chem Rev 99:2499-2510.
54. Rotin D, Staub O, and Haguenauer-Tsapis R (2000) Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J Membr Biol 176:1-17.
55. Safaei R (2006) Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234:34-39.
56. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, and Howell SB (2004) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53:239-246. (Pubitemid 38293722)
57. Safaei R, Maktabi MH, Blair BG, Larson CA, and Howell SB (2009) Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem 103:333-341.
58. Safaei R, Otani S, Larson BJ, Rasmussen ML, and Howell SB (2008) Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol 73:461-468. (Pubitemid 351159216)
59. Samimi G and Howell SB (2006) Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 57:781-788.
60. Samimi G, Katano K, Holzer AK, Safaei R, and Howell SB (2004a) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25-32. (Pubitemid 38822084)
61. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, and Howell SB (2004b) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661-4669. (Pubitemid 38955516)
62. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, and Howell SB (2003) Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 9:5853-5859. (Pubitemid 38018067)
63. Sarna S, Bhola RK, and Sodhi A (1988) Release of protein bound sialic acid from fibrosarcoma cells after cis-dichlorodiammine platinum (II) treatment: the possible role in tumor regression. Pol J Pharmacol Pharm 40:295-302.
64. Sinani D, Adle DJ, Kim H, and Lee J (2007) Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 282:26775-26785. (Pubitemid 47501950)
65. Sodhi A and Prasad SB (1985) Differential binding of conA and WGA on the cell surface, the role of sialic acid in their expression and the increased activity of sialidase after cis-platin treatment. Experientia 41:93-95.
66. Song IS, Chen HH, Aiba I, Hossain A, Liang ZD, Klomp LW, and Kuo MT (2008) Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 74:705-713.
67. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, and Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3:1543-1549.
68. Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, and Rotin D (1996) WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J 15:2371-2380.
69. Sze CM, Khairallah GN, Xiao Z, Donnelly PS, O'Hair RA, and Wedd AG (2009) Interaction of cisplatin and analogues with a Met-rich protein site. J Biol Inorg Chem 14:163-165.
70. 2+ model adducts. Am Chem Soc 38:1450-1455.
71. Wu X, Sinani D, Kim H, and Lee J (2009a) Copper transport activity of yeast Ctr1 is down-regulated via its C terminus in response to excess copper. J Biol Chem 284:4112-4122.
72. Wu Z, Liu Q, Liang X, Yang X, Wang N, Wang X, Sun H, Lu Y, and Guo Z (2009b) Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1. J Biol Inorg Chem 14:1313-1323.
73. Xiao D, Vera MD, Liang B, and Joullié MM (2001) Total synthesis of a conformationally constrained didemnin B analog. J Org Chem 66:2734-2742.
74. Xiao Z, Loughlin F, George GN, Howlett GJ, and Wedd AG (2004) C-terminal domain of the membrane copper transporter Ctr1 from Saccharomyces cerevisiae binds four Cu(I) ions as a cuprous-thiolate polynuclear cluster: sub-femtomolar Cu(I) affinity of three proteins involved in copper trafficking. J Am Chem Soc 126:3081-3090.
75. Xiao Z and Wedd AG (2002) A C-terminal domain of the membrane copper pump Ctr1 exchanges copper(I) with the copper chaperone Atx1. Chem Commun Camb 6:588-589.
76. Zhang LJ, Li ZQ, Yang YP, Li XW, and Ji JF (2009) Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via enhancing p53 protein nuclear export. Mol Cell Biochem 327:171-182.
77. Zhou B and Gitschier J (1997) hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 94:7481-7486.
78. Zimmermann T, Zeizinger M, and Burda JV (2005) Cisplatin interaction with cysteine and methionine, a theoretical DFT study. J Inorg Biochem 99:2184-2196.
79. Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, and Jaehde U (2007) Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73:298-307.